Panagene Inc
KOSDAQ:046210
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 5-Year Average (20.2), the stock would be worth ₩-1 470.64 (165% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -30.9 | ₩2 250 |
0%
|
| 5-Year Average | 20.2 | ₩-1 470.64 |
-165%
|
| Industry Average | 43.9 | ₩-3 190.16 |
-242%
|
| Country Average | 12.5 | ₩-912.25 |
-141%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
P
|
Panagene Inc
KOSDAQ:046210
|
101.5B KRW | -30.9 | 60.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | 19.7 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 14.1 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 15.1 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 22.1 | 28.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 42.3 | 38.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 13 | 30.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.8 |
| Median | 12.5 |
| 70th Percentile | 23.2 |
| Max | 13 874.5 |
Other Multiples
Panagene Inc
Glance View
PANAGENE Inc. engages in the molecular diagnostics business. The company is headquartered in Daejeon, Daejeon and currently employs 71 full-time employees. The company went IPO on 2000-08-16. The firm develops selective deoxyribonucleic acid (DNA) amplification technology and detection technology which used in the drug susceptibity testing, single nucleotide sequence variation inspection, infectious diseases hospital inspection and other DNA relates diseases inspection. The Company’s customs mainly include DAKO, AdvanDx, Abbott, LSI Medience Corporation and others.
